DDInter1956 DDInter1824
A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflammatory and autoimmune disorders, such as different types of arthritis and cytokine release syndrome. It was later approved by Health Canada on 30 April 2010. After being investigated to treat severely ill patients with COVID-19,[A193278,L12837,L12843] tocilizumab was approved by the European Commission in December 2021 to treat COVID-19 in adults receiving systemic corticosteroids and supplemental oxygen or mechanical ventilation. Subsequently, it was granted approval by Health Canada and the FDA in October and December 2022, respectively. Tocilizumab-bavi, a biosimilar drug, was approved by the FDA in September 2023.
Zalcitabine {u} (Compound) resembles {v} (Compound) Didanosine
Didanosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Zalcitabine {u} (Compound) resembles {v} (Compound) Cytarabine
Cytarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tocilizumab
Zalcitabine {u} (Compound) resembles {v} (Compound) Didanosine
Didanosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ixabepilone
Ixabepilone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Zalcitabine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Isradipine
Isradipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Zalcitabine {u} (Compound) resembles {v} (Compound) Cytarabine
Cytarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zidovudine
Zidovudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Zalcitabine {u} (Compound) causes {v} (Side Effect) Visual impairment
Visual impairment {u} (Side Effect) is caused by {v} (Compound) Isradipine
Isradipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Zalcitabine {u} (Compound) resembles {v} (Compound) Cytarabine
Cytarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Lurbinectedin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Zalcitabine {u} (Compound) causes {v} (Side Effect) Hepatitis
Hepatitis {u} (Side Effect) is caused by {v} (Compound) Pitavastatin
Pitavastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Zalcitabine {u} (Compound) resembles {v} (Compound) Cytarabine
Cytarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Thalidomide
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Zalcitabine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Etravirine
Etravirine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Zalcitabine (Compound) resembles Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Zalcitabine (Compound) resembles Cytarabine (Compound) and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tocilizumab
Zalcitabine (Compound) resembles Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Zalcitabine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Zalcitabine (Compound) resembles Cytarabine (Compound) and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Zalcitabine (Compound) causes Visual impairment (Side Effect) and Visual impairment (Side Effect) is caused by Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Zalcitabine (Compound) resembles Cytarabine (Compound) and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin and Lurbinectedin may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Zalcitabine (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Pitavastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Zalcitabine (Compound) resembles Cytarabine (Compound) and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Cytarabine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Zalcitabine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etravirine (Compound) and Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab